# Eosinophilic inflammation in hereditary angioedema: a single-center real-world retrospective chart review study

**Authors:** Katharina Boch, Ralf J. Ludwig, Dagmar von Bubnoff, Andreas Recke

PMC · DOI: 10.3389/fimmu.2026.1754405 · Frontiers in Immunology · 2026-02-17

## TL;DR

This study finds that patients with hereditary angioedema show signs of increased eosinophil activation, suggesting a new inflammatory component to the disease.

## Contribution

The study is the first to systematically investigate eosinophil involvement in hereditary angioedema.

## Key findings

- HAE patients had a 1.52-fold increase in serum ECP levels compared to controls.
- Eosinophil activation was observed without an increase in absolute eosinophil counts.
- The findings suggest a new inflammatory mechanism beyond bradykinin in HAE.

## Abstract

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks primarily driven by bradykinin-mediated vascular permeability. However, additional inflammatory mechanisms may contribute to disease heterogeneity. During routine diagnostics, we observed elevated serum eosinophil cationic protein (ECP) levels in HAE patients, suggesting increased eosinophil activation. To date, eosinophil involvement in HAE has not been systematically investigated, this study aimed to validate clinical observations and explore a potential link between bradykinin signaling and eosinophilic inflammation.

We retrospectively analyzed data from 48 patients with confirmed HAE (32 HAE type I/II, 16 HAE with normal C1-INH) and 1,880 control patients treated at a tertiary university allergy and angioedema referral center. Using causal-inference Bayesian multilevel regression with bias-breaking post-stratification and propensity-score inverse probability weighting, we estimated the effect of HAE on serum ECP levels and absolute eosinophil counts while adjusting for age, sex, season, and allergic comorbidities.

HAE was associated with a 1.52-fold average increase in serum ECP levels (most conservative 95% credibility interval: 1.24–1.90; Bayesian p = 0.00088), consistent across all modeling specifications. Absolute eosinophil counts were not elevated, indicating enhanced eosinophil activation independent of cell number.

Patients with HAE show biochemical evidence of increased eosinophil activation, suggesting a previously unrecognized inflammatory component beyond bradykinin-driven edema formation. Further studies should clarify clinical implications and the potential contribution to comorbidities and phenotypic variability.

## Linked entities

- **Proteins:** bdkrb2 (bradykinin receptor B2), SERPING1 (serpin family G member 1)
- **Diseases:** hereditary angioedema (MONDO:0019623)

## Full-text entities

- **Genes:** C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, F12 (coagulation factor XII) [NCBI Gene 2161] {aka HAE3, HAEX, HAF}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, ANGPT1 (angiopoietin 1) [NCBI Gene 284] {aka AGP1, AGPT, AGPT-1, ANG1, HAE5}, LGALS3 (galectin 3) [NCBI Gene 3958] {aka CBP35, GAL3, GALBP, GALIG, L31, LGALS2}, CPN1 (carboxypeptidase N subunit 1) [NCBI Gene 1369] {aka CPN, SCPN}, DAB2IP (DAB2 interacting protein) [NCBI Gene 153090] {aka AF9Q34, AIP-1, AIP1, DIP1/2}, MYOF (myoferlin) [NCBI Gene 26509] {aka FER1L3, HAE7}, KLK4 (kallikrein related peptidase 4) [NCBI Gene 9622] {aka AI2A1, ARM1, EMSP, EMSP1, KLK-L1, PRSS17}, KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, HS3ST6 (heparan sulfate-glucosamine 3-sulfotransferase 6) [NCBI Gene 64711] {aka 3-OST-6, 3OST6, HAE8, HS3ST5}, RNASE3 (ribonuclease A family member 3) [NCBI Gene 6037] {aka ECP, RAF1, RNS3}
- **Diseases:** -C1INH (MESH:D054179), Gleich's syndrome (MESH:D005359), DRESS (MESH:D063926), autoimmune/lymphoproliferative disease (MESH:D056735), endothelial dysfunction (MESH:D014652), abdominal pain (MESH:D015746), eosinophilia (MESH:D004802), edema (MESH:D004487), allergic asthma (MESH:D001249), airway inflammation (MESH:D007249), mastocytosis (MESH:D008415), sinusitis (MESH:D012852), genetic disorder (MESH:D030342), airway obstruction (MESH:D000402), HAE type I/II (MESH:D056829), nasal polyps (MESH:D009298), urticaria (MESH:D014581), allergic rhinitis (MESH:D065631), nasal polyposis (MESH:D009668), vascular dysfunction (MESH:D002561), food allergy (MESH:D005512), pollen allergies (MESH:D006255), mast-cell (MESH:D000090362), angioedema (MESH:D000799), type 2 inflammatory diseases (MESH:C563310), acquired angioedema (MESH:C538173), hypereosinophilic syndromes (MESH:D017681), II (MESH:C537730), rhinosinusitis (MESH:D000092562), D84.1 (MESH:C538557), atopic dermatitis (MESH:D003876), tissue (MESH:D017695), ATT (MESH:D019553), chronic (MESH:D002908), rhinitis (MESH:D012220), HAE-C1INH (MESH:D056828), allergic (MESH:D004342)
- **Chemicals:** EDTA (MESH:D004492), sebetralstat (MESH:C000726128), HAE-nC1INH (-), omalizumab (MESH:D000069444), lanadelumab (MESH:C000596550), cobalt (MESH:D003035), berotralstat (MESH:C000706836)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HAE-nC1INH — Homo sapiens (Human), Hereditary angioedema, Transformed cell line (CVCL_WA80)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953394/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953394/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953394/full.md

---
Source: https://tomesphere.com/paper/PMC12953394